Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Proactive management of topoisomerase-1 ADC payload toxicities requires upgrading antiemetic regimens by adding neurokinin-1 inhibitors such as aprepitant to standard ondansetron and dexamethasone. Dr. Alvarez-Secord also utilizes upfront growth factor support for at-risk patients and prompt anti-motility treatment to prevent dose interruptions.

Related Insights

The nausea from the ADC trastuzumab deruxtecan can be severe and prolonged, comparable to highly emetogenic agents like cisplatin. Clinicians should proactively use an aggressive anti-emetic regimen, treating it like a platinum-based therapy to maintain patient quality of life and treatment adherence.

Data from a novel Nectin-4 ADC trial showed zero responses in patients with prior topoisomerase therapy. This strongly suggests that payload resistance, not just the ADC target, is a critical mechanism that will dictate future treatment sequencing.

This is a crucial concept for predicting ADC toxicities. ADCs with a topoisomerase payload (like TDXD) cause nausea and myelosuppression, while those with a tubulin inhibitor payload (like MERV) cause neuropathy and ocular issues.

Drawing lessons from T-DXD, experts treat newer exatecan-payload ADCs like RDXD as highly emetogenic from the first dose. Instead of a 'wait and see' approach, they recommend aggressive premedication with a triple-drug antiemetic regimen to prevent nausea and maintain quality of life.

With multiple ADCs available, an emerging sequencing strategy is to alternate between different mechanisms of action, such as following a microtubule toxin-based ADC with a topoisomerase-1 inhibitor payload. This approach aims to avoid compounding specific toxicities, like neuropathy, and potentially circumvent resistance, though it is a strategy born from logic rather than clinical trial data.

To manage the acute GI toxicity of T-DXd, a preemptive three-drug antiemetic combination is recommended. Completely preventing nausea and vomiting is crucial not just for comfort, but for mitigating patient anxiety around chemotherapy and ensuring they can remain on this long-term treatment.

Topoisomerase I payloads in ADCs carry a high risk of neutropenia, a toxicity that has caused previous trials to fail. Future Phase 3 studies, particularly in prostate cancer, must incorporate proactive management strategies like prophylactic GCSF to mitigate this risk, which is considered a critical success factor.

Nausea with TDXD is severe enough that the drug is now considered highly emetogenic. The standard of care is a prophylactic three-drug antiemetic regimen (NK1 antagonist, 5HT3 antagonist, and dexamethasone). Waiting for nausea to occur before treating is a clinical error; prevention is paramount.

For managing nausea from ADCs like TDXD, a three-drug prophylactic regimen (steroid, 5-HT3 antagonist, NK1 inhibitor) is recommended. For delayed nausea, continuing the 5-HT3 antagonist on days two and three is often effective before needing to add agents like olanzapine.

In the absence of definitive data, a practical strategy is emerging to alternate ADC payloads, such as switching from a microtubule toxin to a topoisomerase inhibitor. This approach aims to avoid compounding toxicities like neuropathy and potentially circumvent drug resistance mechanisms.

Adding Aprepitant and Upfront Growth Factors Preserves Dosing Intensity with Topo-1 ADCs | RiffOn